Halotestin (Fluoxymesterone) — Dosing, Cycles, Half-Life & Side Effects

Halotestin (Fluoxymesterone) is an oral anabolic-androgenic steroid with a half-life of 9.2 hours. Extremely potent oral steroid for strength with minimal mass gains, highly hepatotoxic. Primary risks include significant hepatotoxicity, strong HPTA suppression, liver stress typical of 17α-alkylated orals. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassOrals
Half-life9.2 hours
Detection window60 days
AromatizationNo
HepatotoxicityVery High
Suppression9/10
17α-alkylatedYes
Administrationoral

Typical Dosing Ranges

Common dose range: 10-40mg/day

Cycle length: 2-4 weeks

Time to steady state: ~2 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

PCT Requirements

  • This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
  • Depot clearance estimate: ~2 days post-last-dose before SERM start (5 × apparent depot half-life of 9.2h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Severe hepatotoxicity
  • Extreme suppression
  • High cost
  • Minimal muscle gains

Known Interactions

No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Liver enzymes (ALT, AST, GGT) every 2–4 weeks on oral 17αα cycles
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Halotestin (Fluoxymesterone)?

Halotestin (Fluoxymesterone) has a half-life of approximately 9.2 hours. Clearance estimate: 9.2h × 5 = 46h = 1.9 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Halotestin (Fluoxymesterone)?

Commonly reported ranges for Halotestin (Fluoxymesterone): 10-40mg/day. Cycle length: 2-4 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Halotestin (Fluoxymesterone) suppress natural testosterone?

Halotestin (Fluoxymesterone) causes severe suppression of the HPTA axis (score 9/10). Post-cycle therapy (PCT) is recommended after use.

Is Halotestin (Fluoxymesterone) liver toxic?

Hepatotoxicity rating: Very High. Halotestin (Fluoxymesterone) is 17α-alkylated, which bypasses first-pass liver metabolism and increases hepatic stress. Oral 17αα cycles should be capped at 6 weeks and paired with liver monitoring (ALT/AST every 2–4 weeks).

Does Halotestin (Fluoxymesterone) aromatize to estrogen?

Aromatization profile: No. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.

What is Halotestin (Fluoxymesterone) typically used for?

Halotestin (Fluoxymesterone) is commonly used for: Powerlifting, Pre-competition, Strength plateaus. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. FDA prescribing information (NDA historical). 2004. FDA NDA (fluoxymesterone) — Half-life 9.2 hours per FDA prescribing information
  2. FDA prescribing information. 2004. FDA NDA (fluoxymesterone) — FDA black box for hepatotoxicity; peliosis hepatis and hepatocellular carcinoma documented
  3. Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
  4. Hervey GR, Knibbs AV, et al. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin Sci (Lond). 1981. PMID: 7018798
  5. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-21. PMID: 18500378

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Halotestin (Fluoxymesterone). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content